Linifanib
| Title | Journal |
|---|---|
| A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. | Nature chemical biology 20151201 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. | Leukemia & lymphoma 20120801 |
| 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). | Bioorganic & medicinal chemistry letters 20120715 |
| FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model. | Cancer chemotherapy and pharmacology 20120601 |
| An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. | Cancer chemotherapy and pharmacology 20120601 |
| A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. | Cancer chemotherapy and pharmacology 20120401 |
| BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. | British journal of cancer 20120131 |
| Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. | European journal of cancer (Oxford, England : 1990) 20111201 |
| A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy. | NMR in biomedicine 20111101 |
| Comprehensive analysis of kinase inhibitor selectivity. | Nature biotechnology 20111030 |
| Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801 |
| Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). | Bioorganic & medicinal chemistry 20110715 |
| ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models. | The Journal of pharmacology and experimental therapeutics 20110701 |
| Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. | European journal of medicinal chemistry 20110601 |
| The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. | Molecular cancer therapeutics 20110601 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | Chemistry & biology 20101124 |
| Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. | Oncotarget 20101101 |
| Linifanib. | Drugs in R&D 20100701 |
| ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. | Molecular cancer therapeutics 20100301 |
| Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. | European journal of medicinal chemistry 20100101 |
| Pulse-modulated second harmonic imaging microscope quantitatively demonstrates marked increase of collagen in tumor after chemotherapy. | Journal of biomedical optics 20100101 |
| Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001 |
| Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. | The Journal of pharmacology and experimental therapeutics 20090601 |
| Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. | Blood 20090423 |
| ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. | Journal of cardiovascular pharmacology 20090201 |
| ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. | Journal of hematology & oncology 20090101 |
| Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt. | Journal of pharmaceutical and biomedical analysis 20081201 |
| ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. | Journal of hepatology 20081201 |
| 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. | Journal of medicinal chemistry 20080710 |
| In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. | Leukemia research 20080701 |
| 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases. | Journal of medicinal chemistry 20080313 |
| Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. | Leukemia 20080101 |
| Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. | Bioorganic & medicinal chemistry letters 20080101 |
| A quantitative analysis of kinase inhibitor selectivity. | Nature biotechnology 20080101 |
| ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. | Blood 20070415 |
| Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. | Journal of medicinal chemistry 20070405 |
| Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060801 |
| Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. | Molecular cancer therapeutics 20060401 |
| Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. | Molecular cancer therapeutics 20060401 |
| A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in human plasma samples. | Rapid communications in mass spectrometry : RCM 20060101 |
| A high-throughput liquid chromatography/tandem mass spectrometry method for simultaneous quantification of a hydrophobic drug candidate and its hydrophilic metabolite in human urine with a fully automated liquid/liquid extraction. | Rapid communications in mass spectrometry : RCM 20060101 |